Age, Biography and Wiki

Francisco J. Quintana was born on 30 April, 1974. Discover Francisco J. Quintana's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is He in this year and how He spends money? Also learn how He earned most of networth at the age of 49 years old?

Popular As N/A
Occupation N/A
Age 50 years old
Zodiac Sign Taurus
Born 30 April, 1974
Birthday 30 April
Birthplace N/A
Nationality

We recommend you to check the complete list of Famous People born on 30 April. He is a member of famous with the age 50 years old group.

Francisco J. Quintana Height, Weight & Measurements

At 50 years old, Francisco J. Quintana height not available right now. We will update Francisco J. Quintana's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.

Physical Status
Height Not Available
Weight Not Available
Body Measurements Not Available
Eye Color Not Available
Hair Color Not Available

Who Is Francisco J. Quintana's Wife?

His wife is Tamara Kremer Mecabell

Family
Parents Not Available
Wife Tamara Kremer Mecabell
Sibling Not Available
Children 2

Francisco J. Quintana Net Worth

His net worth has been growing significantly in 2022-2023. So, how much is Francisco J. Quintana worth at the age of 50 years old? Francisco J. Quintana’s income source is mostly from being a successful . He is from . We have estimated Francisco J. Quintana's net worth , money, salary, income, and assets.

Net Worth in 2023 $1 Million - $5 Million
Salary in 2023 Under Review
Net Worth in 2022 Pending
Salary in 2022 Under Review
House Not Available
Cars Not Available
Source of Income

Francisco J. Quintana Social Network

Instagram
Linkedin
Twitter
Facebook
Wikipedia
Imdb

Timeline

2020

20. Giovannoni F., Bosch I., Polonio M.C., Torti M.F., Wheeler M.A., Li Z., Romorini L., Rodriguez Varela M.S., Rothhammer V., Barroso A., Tjon E. C., Sanmarco L. M., Takenaka M.C, Modaresi S., Gutiérrez-Vázquez C., Ghabdan Zanluqui N., Barreto dos Santos N., Demarchi Munhoz C., Wang Z., Damonte E.B., Sherr D., Gehrke L., Schatzmann Peron J.P., Garcia C.G. and Quintana F.J. AHR is a Zika virus host factor and a candidate target for antiviral therapy. Nature Neuroscience 23, 939-51 (2020).

21. Wheeler MA, Clark IC, Tjon EC, Li Z, Zandee SEJ, Couturier CP, Watson BR, Scalisi G, Alkwai S, Rothhammer V, Rotem A, Heyman JA, Thaploo S, Sanmarco LM, Ragoussis J, Weitz D, Petrecca K, Moffitt JR, Becher B, Antel JP, Prat A, Quintana FJ. Genomic control of astrocytes in multiple sclerosis. Nature. 578, 593-599 (2020).

2019

16. Takenaka M.C., Gabriely G., Rothhammer V., Mascanfroni I.D., Wheeler M.A., Chao C.C., Gutiérrez-Vázquez C., Kenison J., Tjon E.C., Barroso A., Vandeventer T., Alves de Lima K., Rothweiler S., Ghannam S., Zandee S., Healy L., Sherr D., Farez M. F., Pratt A., Antel J., Reardon D.A., Zhang H., Robson S.C., Getz G., Weiner H.L. and Quintana F.J. Control of tumor-associated macrophages and T-cells in glioblastoma via AHR and CD39. Nature Neuroscience 22, 729-740 (2019).

17. Wheeler MA, Jaronen M, Covacu R, Zandee SEJ, Scalisi G, Rothhammer V, Tjon EC, Chao CC, Kenison JE, Blain M, Rao VTS, Hewson P, Barroso A, Gutiérrez-Vázquez C, Prat A, Antel JP, Hauser R and Quintana FJ. Environmental control of astrocyte pathogenic activities in CNS inflammation. Cell 176, 581-596 (2019).

2018

15. Rothhammer V, Borucki DM, Tjon EC, Takenaka MC, Chao CC, Ardura-Fabregat A, de Lima KA, Gutiérrez-Vázquez C, Hewson P, Staszewski O, Blain M, Healy L, Neziraj T, Borio M, Wheeler M, Dragin LL, Laplaud DA, Antel J, Alvarez JI, Prinz M, Quintana FJ. Microglial control of astrocytes in response to microbial metabolites. Nature 557, 724-728 (2018).

2016

13. Yeste, A., Takenaka, M.C., Mascanfroni, I.D., Nadeau, M., Kenison, J.E., Patel, B., Tukpah, A.M., Babon, J.A., DeNicola, M., Kent, S.C., Pozo, D. & Quintana, F.J. Induction of SOCS2 by tolerogenic nanoparticles arrests the diabetogenic T cell response. Science Signaling 9(433):ra61 (2016). Not Federally Funded.

14. Rothhammer V, Mascanfroni ID, Bunse L, Takenaka MC, Kenison J, Mayo L, Chao CC, Patel B, Yan R, Blain M, Alvarez JI, Kébir H, Anandasabapathy N, Izquierdo G, Jung S, Obholzer N, Pochet N, Clish CB, Prinz M, Prat A, Antel J & Quintana FJ. Modulation of astrocyte activity by type I interferon and dietary tryptophan limits inflammation in the central nervous system. Nature Medicine 22, 586-97 (2016).  Not Federally Funded

2015

11. Mascanfroni ID, Takenaka MC., Yeste A, Patel B, Wu Y, Kenison J, Siddiqui S, Basso AS, Otterbein LE, Pardoll DM, Pan F, Priel A, Clish CB, Robson SC, Quintana FJ. Metabolic control of Tr1 cell differentiation by AHR and HIF1-α. Nature Medicine 21, 638-646 (2015).

2012

7. *Quintana, FJ, *Jin, H., Burns, E.J., Nadeau, M., Yeste, A., Kumar, D., Rangachari, M., Zhu, C., Xiao, S., Seavitt, J., Georgopoulos, K., Kuchroo, V.K. Aiolos promotes T(H)17 differentiation by directly silencing Il2 expression. Nature Immunology 13, 770-7 (2012).

2010

4. *Apetoh L., *Quintana FJ, *Pot C., Joller N., Xiao S., Kumar D., Burns E.J., Sherr D.H., Weiner H.L. and Kuchroo V.K. The Aryl hydrocarbon Receptor (AhR) interacts with c-Maf to promote the differentiation of IL-27-induced TR1 cells. Nature Immunology 11, 854- 61 (2010).

5. Gandhi R., Kumar D., Burns E.J., Nadeau M., Dake B., Laroni A., Kozoriz D., Weiner H.L. and Quintana FJ. Aryl hydrocarbon receptor activation induces human Tr1-like and Foxp3 Treg cells. Nature Immunology 11, 846-53 (2010).

2009

3. *Farez, M.F., *Quintana F.J., Gandhi, R., Izquierdo, G., Lucas, M. & Weiner, H.L. TLR2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE. Nature Immunology 10, 958-964 (2009).  Corresponding author.

2008

2. Quintana, FJ, Basso, A.S., Iglesias, A.H., Korn, T., Farez, M.F., Bettelli, E., Caccamo, M., Oukka, M. & Weiner, H.L. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 453, 65-71 (2008).

2004

Dr. Quintana received his Diploma in Biology from the University of Buenos Aires. He received his PhD in Immunology from the Weizmann Institute of Science in 2004, where he was advised by Dr. Irun Cohen. Dr. Quintana joined Brigham and Women's Hospital and Harvard Medical School as a postdoctoral fellow in 2005 where he was advised by Dr. Howard L. Weiner. In 2018, Dr. Quintana was appointed Professor of Neurology with tenure. Dr. Quintana is also an Associate Member of the Broad Institute of MIT and Harvard. Dr. Quintana is the president of International Society of Neuroimmunology (2021–2023).

Dr. Quintana has received multiple awards including the Lady Anne Chain Prize for Academic and Scientific Achievements (2004), the Junior Investigator Award from the National MS Society for Outstanding Research (2008), the NIH Pathway to Independence Award (2009), the Nature Publications Award for Outstanding Research Achievements (2009), the Harry Weaver Research Scholar Award (2014), the Harvard Medical School Young Mentor Award (2016), the Milestone in MS Research Award (2017), the American Association of Immunologists-BD Biosciences Investigator Award (2019), ISI Most Highly Cited List since 2019, and the Barancik Prize for Innovation in MS Research (2020). Dr. Quintana is the Indirawati Kuchroo and Charlotte Weiner Distinguished Professor of Neuroimmunology (2021).

1974

Francisco J. Quintana (born April 30, 1974) is an Argentinean-American immunologist and neuroscientist, and Professor of Neurology at Harvard Medical School. His lab studies interactions between the immune system and nervous system. He is best known for his work on the regulation of inflammation by astrocytes, and by the study of the role of the Aryl Hydrocarbon Receptor in the regulation of the immune response by pollutants, the microbial flora and metabolism. Dr. Quintana's research has implications for our understanding of the pathology of multiple inflammatory disorders including multiple sclerosis, Type 1 diabetes and Inflammatory Bowel Disease, and also brain tumors and infectious diseases. His work has also led to the development of novel therapeutic interventions.